Dean Welsch Selected Research

Nausea

10/2022

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dean Welsch Research Topics

Disease

6	Neoplasms (Cancer) 10/2022 - 07/2002
2	Neoplasm Metastasis (Metastasis) 10/2017 - 07/2002
1	Constipation 10/2022
1	Diarrhea 10/2022
1	Fatigue 10/2022
1	Abdominal Pain (Pain, Abdominal) 10/2022
1	Vomiting 10/2022
1	Nausea 10/2022
1	Urinary Tract Infections (Urinary Tract Infection) 11/2014
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 09/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 09/2010
1	Arthritis (Polyarthritis) 09/2010

Drug/Important Bio-Agent (IBA)

2	Immunoconjugates (Immunoconjugate)IBA 01/2018 - 10/2017
2	Matrix Metalloproteinases (MMPs)IBA 09/2010 - 07/2002
1	BiguanidesIBA 10/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 10/2022
1	ulixertinibIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	ProdrugsIBA 01/2018
1	pyrrolo(2,1-c)(1,4)benzodiazepineIBA 10/2017
1	Membrane Proteins (Integral Membrane Proteins)IBA 10/2017
1	fialuridineIBA 11/2014
1	Matrix Metalloproteinase InhibitorsIBA 09/2010
1	piperidineIBA 09/2010
1	N- hydroxy- 1- (2- methoxyethyl)- 4- ((4- (4- (trifluoromethoxy)phenoxy)phenyl)sulfonyl)piperidine- 4- carboxamideIBA 09/2010
1	SulfonesIBA 09/2010

Therapy/Procedure

2	Therapeutics 01/2018 - 10/2017